Premium Peptide Range

Mechanism

Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Widely studied in clinical trials with consistent 10–15% body weight reduction over 68 weeks.

Typical Research Protocol

• Starting dose: 0.25mg weekly for 4 weeks
• Increase to 0.5mg, then 1mg weekly
• Reconstitute with bacteriostatic water (1–2ml)
• Subcutaneous administration

Storage

Keep lyophilised vial at 2–8°C. Reconstituted solution stable for 28 days under refrigeration. Protect from direct light.

Mechanism

Tirzepatide is a dual GIP/GLP-1 receptor agonist. GIP activation enhances insulin secretion and fat metabolism while GLP-1 suppresses appetite — delivering additive weight loss effects seen in SURMOUNT trials (20%+ body weight reduction).

Typical Research Protocol

• Starting dose: 2.5mg weekly
• Titrate by 2.5mg every 4 weeks as tolerated
• Typical maintenance: 10–15mg weekly
• Reconstitute with bacteriostatic water

Storage

Store at 2–8°C before and after reconstitution. Reconstituted solution stable 28 days refrigerated. Do not freeze.

Mechanism

TB-500 (Thymosin Beta-4) regulates actin polymerisation, promoting cell migration and proliferation. It reduces inflammation, supports angiogenesis, and is widely researched for systemic injury recovery and cardiac repair.

Typical Research Protocol

• Loading phase: 2–2.5mg twice weekly for 4–6 weeks
• Maintenance: 2–2.5mg once weekly
• Often stacked with BPC-157 for synergistic healing
• Subcutaneous or intramuscular injection

Storage

Lyophilised powder: store at 4°C. Reconstituted: refrigerate and use within 28 days. Avoid repeated freeze-thaw cycles.

Mechanism

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a naturally occurring copper complex that activates wound healing, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and modulates inflammation — making it one of the most researched regenerative peptides.

Typical Research Protocol

• Topical: dilute in carrier solution, apply to target area 1–2× daily
• Subcutaneous: 1–2mg per injection, 3–5× weekly
• Cycle length: 4–8 weeks
• Often stacked with BPC-157 for enhanced tissue repair

Storage

Store lyophilised powder at 4°C away from light. Reconstituted solution stable at 4°C for up to 21 days. Avoid freeze-thaw cycling once reconstituted.

Mechanism

CJC-1295 (No DAC) is a GHRH analogue with a short half-life (~30 min), producing sharp, physiological GH pulses. Without the DAC moiety, it avoids continuous GH elevation, preserving natural pulsatile release patterns.

Typical Research Protocol

• 100–200mcg injected 2–3× daily
• Best administered before sleep or fasted
• Stack with Ipamorelin for synergistic GH release
• Cycle: 8–16 weeks

Storage

Store lyophilised at −20°C. After reconstitution refrigerate at 4°C, use within 21 days. Do not freeze reconstituted peptide.

Mechanism

IGF-1 LR3 is a modified IGF-1 with an extended half-life (~20–30h), resisting binding proteins to prolong activity. Studied for cellular proliferation, hyperplasia, and recovery.

Typical Research Protocol

• 20–50mcg per day in research models
• Reconstitute with bacteriostatic water
• Cycle: 4–6 weeks

Storage

Store lyophilised at −20°C. After reconstitution refrigerate at 4°C and use within 14 days.

Mechanism

Tesamorelin is a stabilised GHRH analogue that stimulates endogenous GH secretion. Most studied for reducing visceral adipose tissue.

Typical Research Protocol

• 1–2mg daily in research models
• Administered subcutaneously, typically at night
• Cycle: 8–12 weeks

Storage

Store lyophilised at −20°C. After reconstitution refrigerate at 4°C and use within 7 days.